Cardiovascular health, heart failure, atherosclerosis, and cardiac research
334 articles
In obese middle-aged mice, reducing dietary protein—without cutting calories—reversed cardiac inflammation and remodeling via AMPK-ULK1 mitophagy.
Laroprovstat, a once-daily pill, slashed LDL by 80% when combined with rosuvastatin — rivaling injectable PCSK9 inhibitors.
A landmark Circulation review reveals how aging blood vessels accelerate systemic decline — and outlines emerging therapies to stop it.
The American Heart Association's 2026 update outlines evidence-based strategies to slow disease progression and protect grafts after CABG.
The PRINCE trial investigators address scientific critiques of their landmark study on cardiac protection during noncardiac surgery.
A major review reveals how SGLT2 inhibitors protect the heart, kidneys, and metabolism through at least seven distinct biological mechanisms.
Real-world study of 1,559 octogenarians finds SGLT2 inhibitors reduce all-cause death by 42% and heart failure rehospitalization by 31% with no increase in adverse events.
A decade of US data reveals persistent underuse of single-pill combination therapy for hypertension, despite its superiority for blood pressure control.
A major JACC study exposes how secondary prevention after myocardial infarction falls short across the U.S. population.
AI-driven analysis of fat surrounding the heart may unlock a powerful new tool for predicting heart failure before symptoms emerge.
FOURIER and FOURIER-OLE data suggest that earlier initiation of the PCSK9 inhibitor evolocumab may reduce arterial aneurysm events.
The DECISION trial finds low-dose digoxin did not significantly cut hospitalizations or cardiovascular death in 1,001 HFrEF/HFmrEF patients.
